Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.43 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.43 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.43 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.43 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.42 |
| ▸ | PTPRC | P08575 | 1/20 | 0.41 |
| ▸ | PTPRF | P10586 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | CDC25B | P30305 | 1/20 | 0.41 |
| ▸ | SRC | P12931 | 1/20 | 0.41 |
| ▸ | CRHBP | P24387 | 1/20 | 0.41 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.41 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2391431 | 0.89 | SLC6A4 (0.45) | KMT2APTGS2PTGS1ALDH1A1BCL2L1 | |
| SCHEMBL2389486 | 0.86 | MAOB (0.46) | PTGS2PPARAPPARG | |
| SCHEMBL2393686 | 0.85 | BCAT2 (0.48) | KMT2AFGFR1FGFR2FGFR4FGFR3 | |
| SCHEMBL2389641 | 0.84 | HSP90AA1 (0.47) | KMT2APTGS2PTPRCHSP90AA1HSP90AB1 | |
| SCHEMBL2391552 | 0.81 | NPSR1 (0.47) | KMT2APTPRCPTPN1MEN1HPGD | |
| SCHEMBL9890795 | 0.80 | FGFR1 (0.46) | KMT2AFGFR1FGFR2FGFR4FGFR3 | |
| SCHEMBL4120437 | 0.79 | KMT2A (0.50) | KMT2AFGFR1FGFR2FGFR4FGFR3 | |
| SCHEMBL29385679 | 0.79 | KMT2A (0.50) | KMT2AFGFR1FGFR2FGFR4FGFR3 | |
| SCHEMBL4886483 | 0.78 | LMNA (0.50) | KMT2AFGFR1FGFR2FGFR4FGFR3 | |
| SCHEMBL4873147 | 0.76 | TRPA1 (0.46) | KMT2ABCAT2PTGS2PTPRCPTPRF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-54112842-A | — | — | None | — | — | JP | disclosed |
| US-20120142771-A1 | BIPHENYLACETAMIDE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-06-07 | — | — | US | disclosed |
| US-20120142771-A1 | BIPHENYLACETAMIDE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-06-07 | — | — | US | disclosed |
| US-20120142771-A1 | BIPHENYLACETAMIDE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-06-07 | — | — | US | disclosed |
| EP-2374790-A1 | BIPHENYLACETAMIDE DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2011-10-12 | — | — | EP | disclosed |
| EP-2374790-A1 | BIPHENYLACETAMIDE DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2011-10-12 | — | — | EP | disclosed |
| US-20110224304-A1 | BIPHENYLACETAMIDE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2011-09-15 | — | — | US | disclosed |
| US-20110224304-A1 | BIPHENYLACETAMIDE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2011-09-15 | — | — | US | disclosed |
| US-20110224304-A1 | BIPHENYLACETAMIDE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2011-09-15 | — | — | US | disclosed |
| WO-2010055911-A1 | BIPHENYLACETAMIDE DERIVATIVE | 大日本住友製薬株式会社 (JP) | 2010-05-20 | — | — | WO | disclosed |
| JP-S54112842-A | PREPARATION OF ALPHA-BIPHENYLYL-PROPIONIC ACID DERIVATIVE | NIKKEN KAGAKU KK | 1979-09-04 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142771-A1 | BIPHENYLACETAMIDE DERIVATIVE | HRH3, KCNH3, BRPF3 | KMT2A 78/4885FGFR1 294/4885FGFR2 139/4885 |
| US-20110224304-A1 | BIPHENYLACETAMIDE DERIVATIVE | HRH3, KCNH3, BRPF3 | KMT2A 78/4885FGFR1 294/4885FGFR2 139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.